newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt granted Orphan